Universal Updated Phase 1 Data Validates the Feasibility of Allogeneic Anti-BCMA ALLO-715 Therapy for Relapsed/Refractory Multiple Myeloma Mailankody, S., Liedtke, M., Sidana, S., Matous, J. V., Chhabra, S., Oluwole, O. O., Malik, S. A., Kumar, S., Nath, R., Anwer, F., Cruz, J., Jagannath, S., Htut, M., Raje, N. S., Siegel, D. S., Karski, E. E., Lovelace, W., Lourbakos, A., Nandakumar, S., Balakumaran, A., Hari, P. AMER SOC HEMATOLOGY. 2021

View details for DOI 10.1182/blood-2021-145572

View details for Web of Science ID 000736398802191